-

Blackstone Announces Sara Clemens, Former COO at Twitch and Pandora, as Senior Advisor

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced the appointment of Sara Clemens, former Chief Operating Officer at Twitch and Pandora, as a Senior Advisor. Clemens has over 25 years of experience helping lead high-growth companies at the intersection of streaming content and consumer technology. She will advise across Blackstone’s businesses, with a focus on Blackstone Growth (BXG), the firm’s growth equity investing platform.

Vishal Amin, a Managing Director at Blackstone Growth, said: “Sara’s wide-ranging experience at some of the most iconic and distributed consumer technology companies will be invaluable to our portfolio companies and Blackstone’s entrepreneur ecosystem. She knows first-hand the strategic and operational challenges of delivering growth in today’s increasingly global environment.”

Sara Clemens added: “Blackstone has a strong emphasis on providing operational support and benefits of scale to its outstanding set of internet portfolio companies. I’m excited to work with the Blackstone team as they help emerging internet leaders become enduring companies with a global reach.”

As Chief Operating Officer at Twitch, Clemens was responsible for the corporate, revenue and go-to-market functions globally. Previously, she served as COO at Pandora, the internet radio pioneer, and was a member of the Executive Teams at LinkedIn and Xbox. Clemens is currently a Board Member at Duolingo, a leader in online language learning, and Karat, an AI-driven hiring platform for technology companies. She earned a Bachelors and Masters degree from University of Canterbury.

About Blackstone

Blackstone is the world’s largest alternative asset manager. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $881 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, infrastructure, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, Twitter, and Instagram.

Contacts

Tom Clements
(646) 482-6088
Thomas.Clements@blackstone.com

Blackstone

NYSE:BX

Release Versions

Contacts

Tom Clements
(646) 482-6088
Thomas.Clements@blackstone.com

More News From Blackstone

Blackstone Energy Transition Partners Announces Agreement to Acquire Majority Stake in Advanced Cooling Technologies

NEW YORK & LANCASTER, Pa.--(BUSINESS WIRE)--Blackstone (NYSE: BX) and Advanced Cooling Technologies, Inc. (“ACT”) announced today that funds managed by Blackstone Energy Transition Partners (“Blackstone”) have entered into a definitive agreement to acquire a majority stake in ACT, a leading U.S. manufacturer of highly-engineered thermal management and energy efficiency solutions. ACT's executive team will remain in place and continue as significant shareholders in the business. Founded in 2003...

Blackstone Energy Transition Partners Announces Completion of 694MW Magnolia Power Generating Station in Louisiana

NEW YORK & PLAQUEMINE, La.--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced today that private equity funds managed by Blackstone Energy Transition Partners (“Blackstone”) have completed construction of the Magnolia Power Generating Station (“Magnolia Power”), a 694-megawatt greenfield combined cycle gas turbine (“CCGT”) power plant in Plaquemine, Louisiana. Today’s announcement marks the beginning of commercial operations at the plant. Blackstone, through its North American power platform, Ki...

Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (“AML”). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types. Johnson & Johnson and funds managed by BXLS will jointly finance...
Back to Newsroom